Large Pharma Shifts Focus to Early Stage Licensing Deals
by Sam Fazeli, Bloomberg Industries
Early-stage drugs were favored in the second quarter. Large pharmaceutical companies have shifted their attention toward discovering and developing drugs at earlier stages in the development cycle.
Only three deals for Phase III assets (5 percent of the total) were inked in the quarter, compared with six (10 percent) in the second quarter of 2012. Licensing deal volumes remained level in the second quarter as compared to the volumes of a year ago. A total of 60 drug licensing deals were struck.